SEER News and Press, Seer Inc. From 11/09/21

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Seer, Inc. (“Seer” or the “Company”) (NASDAQ: SEER) on behalf of Seer stockholders. Our investigation concerns whether Seer has vio...

Seer (NASDAQ:SEER): Q3 GAAP EPS of -$0.30 misses by $0.01. Revenue of $2.15M (+198.6% Y/Y) beats by $0.92M. Press Release For further details see: Seer EPS misses by $0.01, beats on revenue

REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2021. “We continued to make outstandin...

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Rachel Haurwitz, Ph.D. to serve on its Board of Directors, effective November 8, 2021. Dr. H...

Boston, Massachusetts--(Newsfile Corp. - November 8, 2021) - Block & Leviton is investigating Seer, Inc. (NASDAQ: SEER) for potential securities law violations. Investors who have lost money in their Seer investment should contact the firm to learn more about how they might recover those...

Boston, Massachusetts--(Newsfile Corp. - November 5, 2021) - Block & Leviton is investigating Seer, Inc. (NASDAQ: SEER) for potential securities law violations. Investors who have lost money in their Seer investment should contact the firm to learn more about how they might recover those...

Seer Inc. (NASDAQ:SEER) dropped 7% after a new short call from The Bear Cave. The Bear Cave claims that the company appears to be a "promotional and misleading" biotech company. Seer short interest is 17%. Seer reports Q3 results on Nov. 9. Recall Aug. 12, Seer EPS beats by $0.01, b...

The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....

REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter 2021 after market close on Tuesday, November 9, 2021. C...

The proteomics market size was $21 billion in 2019 and is estimated to increase to $64 billion in 2024 (growing annually at 15%), larger than the genomics market. The company's proteomics diagnostics technology is Proteograph, an integrated solution consisting of consumables, automati...